Intimation Under Regulation 10(6) Of SEBI (SAST) Regulation, 2011.
Intimation under Regulation 10(6) of SEBI (SAST) Regulation, 2011.23-03-2018
23-03-2018
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for IDBI Trusteeship Services Ltd22-03-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for IDBI Trusteeship Services Ltd22-03-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Krishna Prasad Chigurupati22-03-2018
Receipt Of Approval From US FDA For ANDA Filed By Granules India Limited -Reg.
Receipt of approval from US FDA for ANDA filed by Granules India Limited -Reg.19-03-2018
Our Letter Dated 15Th March 2018 W.R.T Intimation Under Regulation 10(5) Of SEBI (SAST) Regulations, 2011
Our letter dated 15th March 2018 w.r.t Intimation under Regulation 10(5) of SEBI (SAST) Regulations, 201116-03-2018
Intimation Under Regulation 10(5) Of SEBI (SAST) Regulations, 2011
Intimation under Regulation 10(5) of SEBI (SAST) Regulations, 201115-03-2018
Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Krishna Prasad Chigurupati15-03-2018
Granules India arm receives EIR report
Granules India on Wednesday informed the exchanges that its subsidiary Granules Pharmaceuticals, Inc has received EIR for its unit located at Chantilly, Virginia. The US FDA28-02-2018
Announcement under Regulation 30 (LODR)-Updates
Receipt of Establishment Inspection Report (EIR) by Granules Pharmaceuticals, Inc. facility from US FDA28-02-2018